



Title:


Certificate of Analysis (CoA)

Date: 5/12/2026
Date Tested: 5/8/2026
Customer: VeriPure
Testing material: Blind_Study_27
Lot Number: unspecified
BT Sample ID: 005000039920413
Labeled Peptide Content/Potency: Unknown
Storage: R.T.
Visual Description: Small clear vial: white sample, holographic label, silver crimp, yellow plastic cap.
Labeled as: Blind_Study_27
Manufacturer: N/A
Testing Purpose: FTIR and HPLC analysis for the identification, purity, potency and composition of a peptide product. It does not provide information on particulate matter, microbial contamination or presence of endotoxins.



| Test | Method | Specification | Result |
|--|---------------|--|--|
| General Appearance | USP <630> | white powder | white powder |
| Mass | USP <41> | As recorded | 65.6 mg |
| FTIR Identification and Composition Analysis | USP <197A> | Sample spectrum should confirm the content of peptide via characteristic bands | FTIR sample spectrum confirms the presence of Tirzepatide with addition of excipient(s)/fillers. |
| HPLC Purity of Peptide Assay | USP <621> | Specifications: $\geq 98\%$ | 99.7 % |
| HPLC Potency Assay | USP <621> | Specifications: blind testing | 21.4 mg |
| Peptide-to-Excipients Ratio | USP <1151> | Recommended ratios of (1:2) to (1:10) for (peptide: excipients) | 21.4 : 44.2 mg (1:2.1) |

The results of the CoA relate only to the item(s) tested and applied to the sample as received.



Andrea Castro, AS
Scientist-II
BTLabs




Verna Zheng, AS
Scientist-II
BTLabs



Title:

Certificate of Analysis (CoA)

FTIR ID and Composition Analysis: Blind Study 27 Lot unspecified



HPLC Purity and Potency Assay @ 280 nm: Blind Study 27 Lot unspecified



Blind Study 27 Lot unspecified @ 280 nm

| Peak #: | Retention Time (min) | Area (mAU*s) |
|---------|----------------------|--------------|
| 1 | 10.678 | 3022.3 |